Cost‐effectiveness of chemoprevention of breast cancer using tamoxifen in a postmenopausal US population

Authors:

Abstract
BACKGROUND: Previous cost‐effectiveness analyses of tamoxifen therapy account for breast cancer risk reduction during active treatment but not for its persistent protective effect after active treatment.METHODS: A detailed, continuous time, mathematical model of breast cancer and healthcare processes was used to simulate a postmenopausal population aged cost saving when higher risk populations were targeted (5‐year risk ≥1.66%). The cost‐effectiveness results were sensitive to parameters that characterized menopausal symptoms and adverse side effects of tamoxifen.CONCLUSIONS: The current results indicated that tamoxifen chemoprophylaxis for postmenopausal women aged <55 years is a cost‐effective health policy that reduces breast cancer incidence and improves life expectancy. Focusing on a postmenopausal population aged <55 years minimized the threat of adverse events associated with tamoxifen. Cancer 2011. © 2011 American Cancer Society.

This publication has 50 references indexed in Scilit: